))
Season 2 - Episode 12: Immune checkpoint inhibitors and the heart - HDL, HDL therapies and cardiovascular risk
Manage episode 409292411 series 3559418
Contenu fourni par European Society of Cardiology. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par European Society of Cardiology ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.
This episode covers:
- Cardiology This Week: A concise summary of recent studies
- Immune checkpoint inhibitors and the heart
- HDL, HDL therapies and cardiovascular risk
- Diagnostics Made Easy: the FBI syndrome
Host: Susanna Price
Guests: Carlos Aguiar, Alexander Lyon, Francois Mach
Want to watch that episode? Go to: https://esc365.escardio.org/event/1147
Disclaimer
This programme is intended for health care professionals only and is to be used for educational purposes.
The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.
Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.
Declarations of interests
Stephan Achenbach, Francois Mach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report.
Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.
Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi. Terumo, Medtronic.
Alexander Lyon has declared to receive speaker, advisory board or consultancy fees and/or research grants from Janssens-Cilag Ltd, Astellas Pharma, Pfizer, Novartis, Servier, Astra Zeneca, Bristol Myers Squibb, GSK, Amgen, Takeda, Roche, Clinigen Group, Eli Lily, Eisai Ltd, Ferring Pharmaceuticals, Boehringer Ingelheim, Akcea Therapeutics, Myocardial Solutions, iOWNA Health and Heartfelt Technologies Ltd.
Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.
42 episodes
Partager
